Axsome Therapeutics News

Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125

Moomoo NewsNov 30 08:32 ET · Ratings

Ladenburg Thalmann Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $175

Moomoo NewsNov 28 05:34 ET · Ratings

Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Madrigal Pharmaceuticals (MDGL)

TipRanksNov 28 05:01 ET · Ratings

Axsome Therapeutics (AXSM) Gets a Buy From RBC Capital

TipRanksNov 27 20:47 ET · Ratings

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

Analyst UpgradesNov 27 13:23 ET

Truist Financial Maintains Axsome Therapeutics(AXSM.US) With Buy Rating

Moomoo NewsNov 27 07:31 ET · Ratings

Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating

Moomoo NewsNov 27 01:31 ET · Ratings

Positive Outlook on Axsome Therapeutics Driven by Promising Clinical Trial Results and Long-term Growth Potential

TipRanksNov 27 01:16 ET

Axsome Therapeutics Says AXS-12 Achieves Primary Endpoint in Late-Stage Narcolepsy Study

MT NewswiresNov 26 08:25 ET

Axsome Therapeutics Reveals AXS-12 Meets Primary Endpoint In ENCORE Long-Term Phase 3 Trial In Narcolepsy

BenzingaNov 26 07:14 ET

Express News | Axsome Therapeutics Inc - Axs-12 Improves Cognition Compared to Placebo

ReutersNov 26 07:01 ET

Express News | Axsome Therapeutics Announces Axs-12 Achieves Primary Endpoint in Encore Long-Term Phase 3 Trial in Narcolepsy

ReutersNov 26 07:00 ET

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

GlobeNewswireNov 26 07:00 ET

Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult

Simply Wall StNov 26 05:53 ET

Axsome Therapeutics Analyst Ratings

BenzingaNov 25 08:17 ET · Ratings

H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $180

Moomoo NewsNov 25 07:31 ET · Ratings

Positive Prescription Trends and Sales Expansion Drive Buy Rating for Axsome Therapeutics

TipRanksNov 25 02:36 ET · Ratings

Cantor Fitzgerald Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $121

Moomoo NewsNov 13 13:31 ET · Ratings

Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up

Zacks Nov 13 10:15 ET

Ladenburg Thalmann Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $175

Moomoo NewsNov 13 09:31 ET · Ratings